Pharma Fund Investment: Should You Continue?

The pharmaceutical industry is a fast-growing sector, with a positive long-term outlook. Pharma funds have offered average returns of around 61% in the last year, with some funds offering returns of over 70%. However, investing in pharma funds is considered risky and is only recommended for aggressive investors with a high-risk tolerance. The performance of pharma funds is dependent on market conditions and the performance of the healthcare sector. While the coronavirus pandemic has increased government spending on healthcare, the industry is subject to volatility and regulatory compliance issues. It is important to carefully consider the advantages and disadvantages of investing in pharma funds, conduct thorough research, and assess one's risk tolerance before making any investment decisions.

What are the advantages of investing in pharma funds?

Investing in pharma funds can be advantageous for several reasons. Here are some of the key advantages:

High Return Potential

Pharma funds offer the potential for high returns if the pharmaceutical and healthcare sectors perform well. The focus on these sectors means that investors can benefit from the growth and performance of companies in these industries. For example, the pharma fund category has offered average returns close to 61% in a year.

Exposure to Leading Pharma Companies

By investing in pharma funds, you gain access to the top pharmaceutical companies in the market. Most pharma funds choose the top-performing stocks, allowing investors to benefit from the potential growth of these industry leaders.

Easy Portfolio Diversification

Sectoral pharma funds simplify the process of diversifying your portfolio to include the pharmaceutical sector. This is less complex than assessing individual pharma stocks and deciding which companies to invest in. Pharma funds invest across market capitalisation, providing a diversified exposure to the sector.

Expert Fund Management

Pharma funds are typically actively managed by expert fund managers who make crucial decisions about stock selection, asset allocation, and investment timing. Investors can benefit from the expertise and experience of these professionals.

Stable Growth Potential

The healthcare and pharmaceutical sectors are considered defensive market segments, which means they are in constant demand and are not as strongly affected by economic downturns. As a result, pharma funds can offer relatively stable growth compared to cyclical sectors that experience more volatile upturns and downturns.

Long-Term Investment Potential

Pharma funds are generally suitable for long-term investment horizons. If you have a long-term outlook and expect the pharmaceutical sector to grow over time, pharma funds can be a good option.

What are the disadvantages of investing in pharma funds?

Investing in pharma funds is not without its risks. Here are some of the disadvantages of investing in pharma funds:

High Risk and Volatility

Pharma funds are considered one of the riskiest types of mutual funds. They are highly volatile and vulnerable to the performance of the pharma and healthcare sectors. If these sectors experience downturns, your investment may suffer significant losses.

Lack of Diversification

Pharma funds are sectoral funds, meaning they invest exclusively in the pharmaceutical and healthcare sectors. This lack of diversification means your investment is entirely dependent on the performance of a single industry. If you invest in pharma funds, ensure it does not exceed 10% of your portfolio.

Timing Sensitivity

To benefit from pharma funds, investors need to time their entry and exit points accurately, which is challenging to do consistently over the long term. Investing in a booming sector after most of the gains have already been realised can lead to disappointment.

Regulatory Risks

The pharmaceutical industry is heavily regulated, and companies must adhere to strict quality standards. Failure to comply with regulatory requirements, such as those imposed by the USFDA, can result in warning letters and negatively impact the performance of pharma funds.

Knowledge and Research Requirements

Investing in pharma funds is best suited for investors with sound knowledge of the pharmaceutical industry and its trends. It is crucial to conduct thorough research before investing, as a lack of understanding can lead to extremely risky bets.

Higher Expense Ratios

Pharma funds typically have higher expense ratios compared to other mutual funds. The annual fee charged by the fund manager for their services can impact your overall returns.

What are the tips for picking pharma funds?

When it comes to picking pharma funds, there are several tips and considerations to keep in mind. Here are some key points to help guide your decision:

• Study the portfolio of the pharma fund: Pharma funds may invest in a diverse range of pharma stocks across market capitalisation. It is important to examine the top holdings of the fund and understand the companies they are investing in.
• Evaluate the fund manager's track record and investment style: Look into the past performance and investment approach of the fund manager. Consider their experience and success rate in the pharma sector.
• Opt for larger-sized pharma funds: Check the assets under management (AUM) and the reputation of the mutual fund house. Larger funds with a strong track record can offer more stability and potentially better returns.
• Consider long-term performance: Choose a pharma fund that has consistently performed well over an extended period, such as five or more years. However, keep in mind that past performance does not guarantee future success.
• Study the expense ratio: The expense ratio is the annual fee charged by the mutual fund for managing your investment. Compare the expense ratios of different pharma funds to find the most cost-effective option.
• Invest through a Systematic Investment Plan (SIP): Investing through an SIP allows you to stagger your investment over time and avoid the need to time the market. This can help reduce the risk associated with volatile pharma stocks.
• Diversify your portfolio: Ensure that your overall investment portfolio is well-diversified and not overly concentrated in the healthcare sector. Pharma funds are already focused on a single sector, so balance your portfolio with other investments.
• Understand the risks: Pharma funds are considered aggressive investments due to their volatility. Make sure you have a high-risk tolerance and are comfortable with the potential for significant losses if the pharma sector underperforms.
• Assess your knowledge and expertise: Investing in pharma funds is best suited for investors with a strong understanding of the pharma industry. If you lack expertise in this sector, consider seeking advice from financial professionals or investing in more diverse mutual funds.
• Long-term investment horizon: Pharma funds typically require a long-term investment horizon. Be prepared to stay invested for the long haul to ride out any short-term fluctuations and maximise potential returns.
• Exit strategy: When investing in pharma funds, always have a clear exit strategy in mind. Know when to exit the fund to minimise potential losses and maximise gains.

Remember, investing in pharma funds carries inherent risks, and it is crucial to thoroughly research and understand the industry, the specific funds, and your own risk tolerance before making any investment decisions.

What are the best pharma funds to invest in?

Investing in mutual funds is a convenient and effective way to create wealth over time. Pharma mutual funds are a specific type of mutual fund that invests in the pharmaceutical sector, which is one of the fastest-growing sectors in India. The pharmaceutical industry is expected to grow by 4.7% annually, reaching $1.45 trillion by 2029.

Aditya Birla Sun Life Pharma & Healthcare Fund

Aditya Birla Sun Life Pharma & Healthcare Fund is an open-ended equity mutual fund with a diversified portfolio of stocks. The fund's expense ratio is 2.19%, which is slightly higher than average but reasonable for an actively managed fund.

SBI Healthcare Opportunities Fund

SBI Healthcare Opportunities Fund has a diversified portfolio of stocks, including investments in Dr. Reddy's Laboratories, Sun Pharma, and Divi's Laboratories. The fund's expense ratio is 2.16%, which is slightly higher but still reasonable for an actively managed fund.

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund is an open-ended equity mutual fund investing in the pharma, healthcare, and diagnostics sectors. The fund includes stocks from companies in pharmaceuticals, biotechnology, and diagnostics. Its top holdings include Dr. Reddy's Laboratories, Cipla, and Lupin. The fund has consistently generated good returns and has a low expense ratio of 1.85%.

Nippon India Pharma Fund

Nippon India Pharma Fund is an open-ended equity mutual fund investing in the pharma and healthcare sectors. Its portfolio includes stocks from companies such as Sun Pharma, Dr. Reddy's Laboratories, and Divi's Laboratories. The fund has consistently performed well and has a low expense ratio of 1.97%.

Franklin India Pharma and Healthcare Fund

Franklin India Pharma and Healthcare Fund aims to generate long-term capital appreciation by investing in the pharma and healthcare sectors. The fund has a diversified portfolio and has delivered solid returns over the long term. Its expense ratio is 2.34%, which is slightly higher but still within an acceptable range for actively managed funds.

Tata India Pharma & HealthCare Fund

Tata India Pharma & HealthCare Fund aims to provide long-term capital appreciation by investing in the pharma and healthcare sectors. Its portfolio includes stocks like Sun Pharma, Dr. Reddy's Laboratories, and Cipla. The fund has consistently delivered good returns, and its direct-growth plan has a low expense ratio of 1.61%.

Mirae Asset Healthcare Fund

Mirae Asset Healthcare Fund aims to generate long-term capital appreciation by investing in the healthcare and allied sectors. Its portfolio includes stocks from companies like Sun Pharma, Dr. Reddy's Laboratories, and Biocon. The fund has consistently performed well, and its expense ratio of 2.16% is reasonable for an actively managed fund.

IDBI Healthcare Fund

IDBI Healthcare Fund invests in equity and equity-related stocks of companies in the healthcare sector. The fund has a diversified portfolio and has consistently delivered solid returns. Its expense ratio is 2.3%, which is reasonable for an actively managed fund.

UTI Healthcare Fund

UTI Healthcare Mutual Fund was launched in 2013 and has generated annualised returns of 19.38%. The fund holds 97.84% investment in equity funds, with the majority in large-cap, mid-cap, and small-cap stocks. It also invests a small portion in debt securities, mainly government securities. The fund has an expense ratio of 2.54%.

DSP Healthcare Funds

DSP Healthcare Funds was launched in 2018 and has delivered 22.15% in annualised returns since then. The fund invests the majority of its assets in domestic equities across market capitalisation. DSP Healthcare Funds is suitable for seasoned investors with a high-risk appetite and knowledge of the market. The fund has an expense ratio of 2.26%.

It is important to note that investing in pharma funds carries inherent risks due to the sector's sensitivity to regulatory changes, drug development failures, and shifts in healthcare policies. Therefore, investors should thoroughly research and understand these risks before making investment decisions.

What is the outlook for the pharma sector in India?

The Indian pharmaceutical market is estimated to reach a value of $130 billion by the end of 2030, with a predicted growth rate of 8-11% in 2023. The global market size of pharmaceutical products is estimated to exceed $1 trillion in 2023.

The Indian pharmaceutical industry is worth approximately $50 billion, with over $25 billion coming from exports. The industry has a positive outlook, with a focus on quality manufacturing, affordable drugs, and the adoption of innovation and technology. The COVID-19 pandemic has also shifted the landscape of the industry, with increased collaboration between the government and the pharmaceutical industry.

Several factors will contribute to the growth of the Indian pharmaceutical market, including government initiatives such as the Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana and Ayushman Bharat Yojana under the National Health Protection Scheme (NHPS). The PLI Scheme, which promotes local manufacturing of APIs, Key Starting Materials (KSMs), and Drug Intermediaries, is also expected to boost the industry.

However, the industry also faces challenges, including inflationary pressures, evolving regulatory norms, and the need to continuously invest in upgrading manufacturing standards to maintain its reputation as a high-quality, reliable supplier of medicines worldwide.

Frequently asked questions